GeoVax Labs Inc (NASDAQ:GOVX) — Market Cap & Net Worth
Market Cap & Net Worth: GeoVax Labs Inc (GOVX)
GeoVax Labs Inc (NASDAQ:GOVX) has a market capitalization of $2.60 Million ($2.60 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29669 globally and #5982 in its home market, demonstrating a -12.69% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GeoVax Labs Inc's stock price $1.17 by its total outstanding shares 2223577 (2.22 Million). Review GOVX total liabilities to assess the company's total debt and financial obligations.
GeoVax Labs Inc Market Cap History: 2015 to 2026
GeoVax Labs Inc's market capitalization history from 2015 to 2026. Data shows change from $2.22 Trillion to $2.60 Million (-72.21% CAGR).
Index Memberships
GeoVax Labs Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #880 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #2793 of 3165 |
Weight: GeoVax Labs Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GeoVax Labs Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GeoVax Labs Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.39x
GeoVax Labs Inc's market cap is 1.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.22 Trillion | $428.08K | -$2.69 Million | 5194290.33x | N/A |
| 2016 | $2.22 Trillion | $828.92K | -$3.27 Million | 2682505.39x | N/A |
| 2017 | $2.22 Trillion | $1.08 Million | -$2.17 Million | 2067924.34x | N/A |
| 2018 | $2.22 Trillion | $963.00K | -$2.56 Million | 2309010.38x | N/A |
| 2019 | $400.24 Million | $1.18 Million | -$2.37 Million | 340.37x | N/A |
| 2020 | $112.74 Million | $1.82 Million | -$2.94 Million | 61.84x | N/A |
| 2021 | $120.74 Million | $385.00K | -$18.53 Million | 313.61x | N/A |
| 2022 | $21.02 Million | $81.00K | -$14.01 Million | 259.50x | N/A |
| 2024 | $5.48 Million | $3.95 Million | -$24.99 Million | 1.39x | N/A |
Competitor Companies of GOVX by Market Capitalization
Companies near GeoVax Labs Inc in the global market cap rankings as of June 18, 2026.
Key companies related to GeoVax Labs Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
GeoVax Labs Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, GeoVax Labs Inc's market cap moved from $2.22 Trillion to $ 2.60 Million, with a yearly change of -72.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.60 Million | +584.21% |
| 2025 | $380.23K | -93.06% |
| 2024 | $5.48 Million | -54.48% |
| 2023 | $12.04 Million | -42.72% |
| 2022 | $21.02 Million | -82.59% |
| 2021 | $120.74 Million | +7.10% |
| 2020 | $112.74 Million | -71.83% |
| 2019 | $400.24 Million | -99.98% |
| 2018 | $2.22 Trillion | 0.00% |
| 2017 | $2.22 Trillion | 0.00% |
| 2016 | $2.22 Trillion | 0.00% |
| 2015 | $2.22 Trillion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of GeoVax Labs Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.60 Million USD |
| MoneyControl | $2.60 Million USD |
| MarketWatch | $2.60 Million USD |
| marketcap.company | $2.60 Million USD |
| Reuters | $2.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marb… Read more